ReviewStem cell research & therapy2026
Liver organoids: a novel platform for mechanistic research and drug screening in anti-liver fibrosis.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatic fibrosis (HF) is a common and pivotal pathological stage in the progression of various chronic liver diseases, characterized by excessive deposition of extracellular matrix (ECM) due to aberrant activation of hepatic stellate cells (HSCs). Traditional research models are limited by species differences and oversimplified microenvironments, failing to meet the demands of precision medicine. Organoid technology, as an emerging three-dimensional (3D) culture system, can closely recapitulate the structural and functional complexity of the human liver, providing a revolutionary tool for HF research. This review systematically summarized the construction strategies and applications of HF organoids. Firstly, the key components and dynamic changes in the HF microenvironment were analyzed. Secondly, organoids derived from primary cells versus stem cells were compared. Thirdly, the methods for constructing fibrotic organoids via cytokine induction, pathological simulation, and genetic engineering were elaborated. Finally, the value and challenges of these models in mechanistic studies, drug screening, and regenerative medicine were discussed. Evidence indicated that multilineage liver organoids can recapitulate the complex interaction network of "hepatocytes-non-parenchymal cells-ECM", providing a highly physiologically relevant platform for elucidating fibrosis mechanisms and developing targeted drugs. Although further optimization in maturation and standardization is needed, HF organoid technology holds great potential to bridge basic research and clinical translation, thereby accelerating the innovation of diagnostic and therapeutic strategies for HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.